Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis

NCT02688985 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02688985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02688985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2016
Completion date
April 11, 2023
Enrollment
131 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, primary progressive, relapsing multiple sclerorsis